PTC Therapeutics, Inc. (PTCT)

NASDAQ: PTCT · IEX Real-Time Price · USD
52.75
+0.74 (1.42%)
Aug 12, 2022 4:00 PM EDT - Market closed
1.42%
Market Cap 3.77B
Revenue (ttm) 618.23M
Net Income (ttm) -555.70M
Shares Out 71.54M
EPS (ttm) -7.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 512,498
Open 52.24
Previous Close 52.01
Day's Range 52.21 - 54.46
52-Week Range 25.01 - 54.46
Beta 0.63
Analysts Buy
Price Target 49.41 (-6.3%)
Earnings Date Aug 4, 2022

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic A... [Read more...]

Industry Biotechnology
IPO Date Jun 20, 2013
CEO Stuart Peltz
Employees 1,167
Stock Exchange NASDAQ
Ticker Symbol PTCT
Full Company Profile

Financial Performance

In 2021, PTCT's revenue was $538.59 million, an increase of 41.45% compared to the previous year's $380.77 million. Losses were -$523.90 million, 19.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is 49.41, which is a decrease of -6.33% from the latest price.

Price Target
$49.41
(-6.33% downside)
Analyst Consensus: Buy
Stock Forecasts

News

PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -27.54% and 13.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

- Total revenue of $166 million, representing 42% year-over-year growth –  - Upstaza™ gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first comm...

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results

SOUTH PLAINFIELD, N.J. , July 21, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022 financ...

Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

- PTC Therapeutics to launch first gene therapy directly administered into the brain - SOUTH PLAINFIELD, N.J. , July 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that U...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciar...

NEW YORK , July 6, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim in...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Th...

PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutatio...

SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m.

Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors

SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors.

PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference

SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42nd Annual Growth Stock ...

Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NA...

FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old

- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date -...

PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conferen...

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -14.84% and 2.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

- $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected i...

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of Americ...

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financ...

PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group an...

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , April 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022, the company approved non-statutory stock options to purchase an aggreg...

PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntingt...

SOUTH PLAINFIELD, N.J. , March 30, 2022  /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Hunt...

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. To Contact Law Firm

New York, New York--(Newsfile Corp. - March 22, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc....

PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

SOUTH PLAINFIELD, N.J., March 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duch...

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?